Taking the complexity out of global track and trace requirements
With time running out, Meditraq launches to simplify serialisation data challenge.
A new serialisation implementation partner has formed to assist the increasing number of companies needing to meet the data requirements of looming global regulation changes.
In general, the pharmaceutical industry has been slow to adopt serialisation. The Tjoa Group started exploring the potential of track & trace in 2007, being one of the first in the world to realise full serialisation and aggregation from blister pocket to pallet in 2008. It is not until recently, however, that the industry has started to introduce regulations such as the EU Falsified Medicines Directive (FMD) and the US Drug Supply Chain Security Act (DSCSA).
"Serialisation is a huge task and those companies who have delayed their preparations are now facing an uphill battle to compliance. For many companies at this late stage, implementing their own solution is simply not achievable due to resource constraints, and for others, cost is a huge barrier. Timing is crucial and it is running out, which is why many companies are turning to partners to help ensure a fully compliant solution is in place ahead of the deadlines," said Dexter Tjoa, Co-founder of Meditraq.
With the pharmaceutical industry struggling to meet serialisation requirements in over 55 countries, Meditraq supports its customers with the deployment of serialisation software solutions.
Part of the Tjoa Group, together with contract packaging organisation (CPO) Tjoapack, the newly formed business provides an outsourced solution to the serialisation data challenge, supporting companies with the implementation and management of technology for the safe and secure exchange of serialisation data.
Commenting on the announcement of the company launch, Dexter Tjoa said: “One of the greatest challenges of complying with global track and trace requirements is the complexity of managing and sharing huge volumes of data throughout the pharmaceutical supply chain.
“Given our team has been involved in the serialisation world for over 25 years through Tjoapack’s contract packaging services, we have recognised a need in the market for greater support to overcome the serialisation data challenge, and this has driven the decision to establish Meditraq. Quite simply, we take care of our customers’ serialisation data requirements, meaning hassle-free compliance with global regulations.”
Meditraq’s services include onboarding all supply chain partners and internal manufacturing sites with the necessary software to ensure serialisation data management and exchange. In addition, it encompasses ongoing support and compliance services such as the management of master data, sending data between relevant parties, monitoring transactions, and solving exceptions involving serialised data.
"Currently, Meditraq’s primary focus is helping our customers to implement level 4 and 5 systems that can cater for serialisation data management and exchange, while also onboarding supply chain partners. Once the compliance deadlines have passed, we will continue to provide ongoing support for our customers in terms of managing and transferring the vast amounts of serialisation data that will be generated. We will also be helping them to adapt as the regulatory landscape evolves, ensuring they remain compliant," said Dexter Tjoa.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.